Tetraphase secures series B funds for antibiotic pipeline
This article was originally published in Scrip
Executive Summary
Tetraphase Pharmaceuticals has raised $10 million in the first tranche of its $25 million series B financing round. The company plans to use the proceeds for development of several antibiotic drug candidates.